Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 7/20 | 0.80 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | CA7 | P43166 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14033557 | 0.93 | METAP1 (0.71) | METAP1CA12CA1CA2CA7 | |
| SCHEMBL31406586 | 0.89 | GSK3B (0.70) | METAP1CA12CA1CA2CA7 | |
| SCHEMBL16543019 | 0.89 | METAP1 (1.00) | METAP1CA12CA1CA2CA7 | |
| SCHEMBL28680183 | 0.89 | METAP1 (0.67) | METAP1CA12CA1CA2CA7 | |
| SCHEMBL8083180 | 0.89 | METAP1 (0.67) | METAP1CA12CA1CA2CA7 | |
| SCHEMBL13848414 | 0.89 | METAP1 (1.00) | METAP1CA12CA1CA2CA7 | |
| SCHEMBL1495340 | 0.89 | METAP1 (0.66) | METAP1CA12CA1CA2CA7 | |
| SCHEMBL16543018 | 0.85 | CGAS (0.70) | METAP1CA12CA1CA2CA7 | |
| SCHEMBL2894955 | 0.84 | METAP1 (1.00) | METAP1MAPTALDH1A1POLBKMT2A | |
| SCHEMBL4096609 | 0.84 | METAP1 (1.00) | METAP1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010225-A2 | METHODS AND COMPOSITIONS FOR TARGETING C-REL | Cornell Research Foundation, Inc. (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120842-A2 | METHODS AND COMPOSITIONS FOR TARGETING C-REL | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-10-25 | — | — | WO | claimed |
| US-9873674-B2 | C-Rel inhibitors and uses thereof | CORNELL UNIVERSITY (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873674-B2 | C-Rel inhibitors and uses thereof | CORNELL UNIVERSITY (US) | 2018-01-23 | — | — | US | disclosed |
| US-20150218109-A1 | C-REL INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-06 | — | — | US | disclosed |
| US-20150218109-A1 | C-REL INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-06 | — | — | US | disclosed |
| WO-2014047232-A2 | C-REL INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014047232-A2 | C-REL INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2014-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218109-A1 | C-REL INHIBITORS AND USES THEREOF | REL, NCOR1, CXCR4 | METAP1 3547/4885CA12 4218/4885CA1 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.